The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients

This publication has 23 references indexed in Scilit:

• Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects
  Pharmacology & Therapeutics, 2007
• Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients
  Pharmacogenetics and Genomics, 2007
• The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs
  Clinical Pharmacokinetics, 2007
• Contribution of CYP2C9, CYP2A6, and CYP2B6 to Valproic Acid Metabolism in Hepatic Microsomes from Individuals with the CYP2C9*1/*1 Genotype
  Toxicological Sciences, 2006
• CYP2C9 allele variants in Chinese hypertension patients and healthy controls
  Clinica Chimica Acta, 2004
• Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens
  Biochemical and Biophysical Research Communications, 2004
• Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes
  The Pharmacogenomics Journal, 2003
• Polymorphisms of CYP2A6 and its practical consequences
  British Journal of Clinical Pharmacology, 2001
• Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish Population
  Biochemical and Biophysical Research Communications, 1999
• Valproic Acid
  Drugs, 1994